Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 340

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 340
---
 tax. Following such redemptions, 238,930 shares of Iris Class A Common Stock remained outstanding.

On October 23, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to, among other things, reduce the enterprise value associated with Liminatus to

<div align='center'>179</div>

TABLE OF CONTENTS

$175 million. On October 31, 2024, the parties to the PIPE Equity Subscription Agreement entered into an amendment to such agreement to reduce the PIPE Investor’s committed purchase of PIPE Shares from 2,500,000 to 1,500,000, and decrease the PIPE Equity Investment from $25 million to $15 million.

On December 9, 2024, Iris filed a proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to extend the date by which Iris must consummate a business combination from December 31, 2024 to March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board). Iris’s stockholders approved the amendments to the Iris Certificate of Incorporation at the special meeting on December 20, 2024. On December 26, 2024, Iris filed with the Secretary of State of the State of Delaware an amendment to its amended and restated certificate of incorporation to change the date by which it must consummate a business combination to March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board).

On December 26, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date to June 30, 2025. Also on December 26, 2024, the parties to the Subscription Agreement entered into an amendment to such agreement to extend the termination date of the agreement to June 30, 2025.

### Results of Operations
Iris has neither engaged in any operations nor generated any revenues to date. Iris’s only activities for the period from November 5, 2020 (inception) through September 30, 2024 were organizational activities, those necessary to prepare for Iris’s initial public offering, and identify a target company for its initial business combination. Iris generates non-operating interest income from cash and cash equivalents and marketable securities held in the Trust Account and changes in the value of warrant liabilities. Iris incurs expenses as a result of being a public company (for legal, financial reporting,